De Backer O, et al. - Since subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves were reported by CT, researchers designed a large randomized trial of 231 individuals to evaluate whether anticoagulation can decrease leaflet motion after transcatheter aortic-valve replacement (TAVR). Individuals who had undergone successful TAVR and who did not have an indication for long-term anticoagulation were assigned randomly to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily). For the prevention of subclinical leaflet-motion abnormalities, a rivaroxaban-based antithrombotic strategy was more effective than an antiplatelet-based strategy, in a substudy of a trial involving patients without an indication for long-term anticoagulation who had undergone successful TAVR. Nevertheless, in comparison with the antiplatelet-based strategy, the rivaroxaban-based strategy was correlated with a higher risk of death or thromboembolic complications and a higher risk of bleeding.